B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic fatigue syndrome
- Focus Therapeutic Use
- Acronyms RituxME
- 11 Apr 2016 Planned End Date changed from 1 May 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov.
- 11 Apr 2016 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov.
- 13 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.